Celldex Therapeutics (CLDX) Net Income towards Common Stockholders (2010 - 2026)

Celldex Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$85.9 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 59.68% year-over-year to -$85.9 million; the TTM figure through Mar 2026 stood at -$326.8 million (down 82.67% YoY), while the FY2025 annual figure was -$661.6 million, down 318.97% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$85.9 million, up from -$109.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$23.0 million in Q1 2022, with the low at -$109.6 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$38.3 million (2023), against an average of -$46.6 million.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders sank 169.23% in 2022, then gained 15.28% in 2023.
• Celldex Therapeutics' Net Income towards Common Stockholders stood at -$26.5 million in 2022, then plunged by 63.5% to -$43.3 million in 2023, then declined by 8.83% to -$47.1 million in 2024, then plunged by 132.59% to -$109.6 million in 2025, then grew by 21.63% to -$85.9 million in 2026.
• Business Quant data shows CLDX's Net Income towards Common Stockholders at -$85.9 million in Q1 2026, -$109.6 million in Q4 2025, and -$67.0 million in Q3 2025.